Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb and Pfizer attend AHA scientific sessions

Bristol-Myers Squibb and Pfizer attend AHA scientific sessions

6th November 2012

Bristol-Myers Squibb and Pfizer are presenting new data one stroke prevention methods for atrial fibrillation at the scientific sessions of the American Heart Association (AHA) this week.

The companies are attending the Los Angeles event in order to showcase results from the Aristotle trial, including two pre-specified sub-analyses that assess the performance of the drug Eliquis in comparison to warfarin.

A detailed analysis of major bleeding rates will be accompanied by an evaluation of the safety and efficacy of Eliquis among patients with prior warfarin experience, while a further sub-analysis will evaluate the drug among patients with prior coronary artery disease.

Moreover, the companies are presenting real-world data analyses providing additional insights, such as the correlation between bleeding and discontinuation, warfarin outcomes in the real world compared to trial data and early ischaemic outcomes.

This comes after Bristol-Myers Squibb and Pfizer announced they will be collaborating with Portola Pharmaceuticals to develop an antidote that reverses the anticoagulant activity of Eliquis and other Factor Xa inhibitors.ADNFCR-8000103-ID-801482740-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.